Dallas, TX -- (SBWIRE) -- 07/21/2015 -- Latest report, "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies mentioned in the report are AbbVie Inc., Adaptimmune Limited, Amgen Inc., Astex Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Bionomics Limited, BioNumerik Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Celldex Therapeutics, Inc., Celon Pharma Sp. z o.o., Celsion Corporation, Cerulean Pharma, Inc., Clovis Oncology, Inc., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Glycotope GmbH, ImmunoGen, Inc., Immunotope, Inc., Johnson & Johnson, MabVax Therapeutics Holdings, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., NeoStem, Inc., Novartis AG, Oasmia Pharmaceutical AB, OBI Pharma, Inc., Oncobiologics, Inc., Oncolytics Biotech Inc., Onxeo SA, Otsuka Holdings Co., Ltd., Oxford BioMedica plc, OXiGENE, Inc., Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Prima BioMed Ltd., PsiOxus Therapeutics, Ltd., Sanofi, Sanofi Pasteur SA, Sotio a.s., Synta Pharmaceuticals Corp., Tesaro, Inc., TetraLogic Pharmaceuticals, Therapeutic Proteins International, LLC, TRACON Pharmaceuticals, Inc., VentiRx Pharmaceuticals, Inc.

Complete report on Epithelial Ovarian Cancer, spread across 382 pages is available at
http://www.rnrmarketresearch.com/epithelial-ovarian-cancer-pipeline-review-h1-2015-market-report.html

Scope

-The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Drugs profile mention in this report includes abexinostat hydrochloride, abiraterone acetate, ABT-898, alisertib, anetumab ravtansine, Antisense Oligonucleotide for Ovarian and Colorectal Cancer, AZD-1775, belinostat, bevacizumab, bevacizumab biosimilar, BNC-105P, birinapant, cabozantinib s-malate, Cancer Stem Cell Therapy, catumaxomab, CDX-1401, Cell Therapy to Target NY-ESO-1 for Oncology, cositecan, CRLX-101, CVac, DCVAC/OvCa, DMUC-4064A, EGEN-001, elesclomol, enadenotucirev, erismodegib, fosbretabulin tromethamine, ganetespib, guadecitabine, IMT-1012, LCL-161, lifastuzumab vedotin, lurbinectedin, LY-2606368, MesoCART, mirvetuximab soravtansine, motolimod, NERX-313E, NERX-505X, nintedanib, niraparib, NSC-748933, OBI-822/821, OPB-111001, paclitaxel, PankoMab-GEX, pelareorep, pembrolizumab, PF-06647263, Procure, Protein to Antagonize Frizzled Receptors for Epithelial Ovarian Cancer, ralimetinib mesylate, regorafenib, rucaparib phosphate, SAR-408701, sorafenib tosylate, trabectedin, TRC-105, trebananib, TroVax, Vaccine for Oncology, vCP-2292, X-82.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=395196
(This is a premium report priced at US$2000 for a single user License.)

Table of Contents
List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H1 2015 16
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Development by Companies, H1 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2015 33
Epithelial Ovarian Cancer - Pipeline by Adaptimmune Limited, H1 2015 34
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2015 35
Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 36
Epithelial Ovarian Cancer - Pipeline by AstraZeneca PLC, H1 2015 37
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2015 38
Epithelial Ovarian Cancer - Pipeline by Bionomics Limited, H1 2015 39
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 40
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 41
Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 42
Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2015 43
Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H1 2015 44
Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 45
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2015 46
Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2015 47
Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2015 48
Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 49
Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H1 2015 50
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2015 51
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2015 52
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H1 2015 53
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2015 54
Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 55
Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H1 2015 56
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 57
Epithelial Ovarian Cancer - Pipeline by NeoStem, Inc., H1 2015 58
Epithelial Ovarian Cancer - Pipeline by Novartis AG, H1 2015 59
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 60
Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H1 2015 61
Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H1 2015 62
Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 63
Epithelial Ovarian Cancer - Pipeline by Onxeo SA, H1 2015 64
Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 65
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H1 2015 66
Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H1 2015 67
Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H1 2015 68
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2015 69
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 70
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2015 71
Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 72
Epithelial Ovarian Cancer - Pipeline by Sanofi, H1 2015 73
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2015 74
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2015 75
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 76
Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H1 2015 77
Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015 78
Epithelial Ovarian Cancer - Pipeline by Therapeutic Proteins International, LLC, H1 2015 79
Epithelial Ovarian Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 80
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 81
Assessment by Monotherapy Products, H1 2015 82
Number of Products by Stage and Target, H1 2015 84
Number of Products by Stage and Mechanism of Action, H1 2015 88
Number of Products by Stage and Route of Administration, H1 2015 91
Number of Products by Stage and Molecule Type, H1 2015 93
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2015 244
Epithelial Ovarian Cancer - Dormant Projects, H1 2015 373
Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H1 2015 374
Epithelial Ovarian Cancer - Discontinued Products, H1 2015 375

Explore more reports on Dermatology therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.